Lanean...
Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia
Ibrutinib is the first in-class, orally administered, Bruton’s tyrosine kinase (BTK) inhibitor that abrogates the critical signaling downstream of the B-cell receptor (BCR). This signaling is required for B-cell survival, proliferation and interaction with the microenvironment. Ibrutinib proved acti...
Gorde:
| Argitaratua izan da: | Ther Adv Hematol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5753924/ https://ncbi.nlm.nih.gov/pubmed/29317997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620717741861 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|